Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626361 | 0.89 | OPRM1 (0.51) | OPRM1MAP4K4DRD2DRD4DRD3 | |
| SCHEMBL648009 | 0.86 | OPRM1 (0.68) | OPRM1MAP4K4DRD2DRD4DRD3 | |
| SCHEMBL15862739 | 0.82 | OPRM1 (0.64) | OPRM1MAP4K4DRD2DRD4DRD3 | |
| SCHEMBL2218 | 0.82 | OPRM1 (0.64) | OPRM1MAP4K4DRD2DRD4DRD3 | |
| SCHEMBL3237390 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1 | |
| SCHEMBL13594179 | 0.81 | OPRM1 (0.60) | OPRM1 | |
| SCHEMBL625655 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1 | |
| SCHEMBL3270477 | 0.81 | OPRM1 (0.40) | OPRM1ALDH1A1 | |
| SCHEMBL2131500 | 0.81 | OPRM1 (0.58) | OPRM1ALDH1A1 | |
| SCHEMBL3903587 | 0.81 | OPRM1 (0.40) | OPRM1MAP4K4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| EP-2681206-B1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| WO-2005077463-A2 | LIGAND FOR A MONOAMINE RECEPTOR OR TRANSPORTER FOR TREATING ADDICTION OR DEPENDENCE | SEPRACOR INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | CUNY GREGORY D (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1318988-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | Sepracor, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002083863-A2 | THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF | SEPRACOR, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | OPRM1 6/4885MAP4K4 2118/4885DRD2 37/4885 |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | OPRM1 513/4885MAP4K4 3196/4885DRD2 329/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | OPRM1 22/4885MAP4K4 3535/4885DRD2 134/4885 |
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | OPRM1 40/4885MAP4K4 3293/4885DRD2 44/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885MAP4K4 3458/4885DRD2 1448/4885 |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885MAP4K4 3458/4885DRD2 1448/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | OPRM1 22/4885MAP4K4 3535/4885DRD2 134/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | OPRM1 40/4885MAP4K4 3293/4885DRD2 44/4885 |
| US-20150283134-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | OPRM1 363/4885MAP4K4 3763/4885DRD2 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.